Catalyst Event
Sanofi (SNY) · Other
From KEDI Tesla Fixed Tech100 Index (KTSLT100)
3/16/2026, 12:00:00 AM
Sanofi entered into a licensing agreement with Sino Biopharmaceutical on March 16, 2026, for its JAK/ROCK inhibitor, rovadicitinib, for up to $1.53 billion, including a $135 million upfront payment.
Korean Translation
사노피, 2026년 3월 16일 시노 바이오파마슈티컬과 JAK/ROCK 억제제 로바디시티닙에 대해 최대 15억 3천만 달러 규모의 라이선스 계약을 체결함.
Related Recent Events
CrowdStrike Holdings Inc (CRWD) · Earnings Release
Next earnings release for Q1 2027 is scheduled for 2026-06-09, with analysts forecasting an EPS of $1.07 estimated.
6/9/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA decision (PDUFA date) for LEQEMBI IQLIK (lecanemab) subcutaneous autoinjector for treatment initiation in Alzheimer's disease on 2026-05-24; high importance is estimated as FDA approval for a major drug formulation typically results in ≥10% price impact, scheduled.
5/24/2026, 12:00:00 AM
Baidu Inc (BIDU) · Earnings Release
Q1 2026 earnings release is scheduled for May 20, 2026. Medium importance is estimated as quarterly earnings typically result in price movements exceeding 5%.
5/20/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
Google I/O 2026 developer conference is scheduled for 2026-05-19. Developer conferences usually have a 1-5% price impact. Updates on AI, Gemini, and Android are expected.
5/19/2026, 12:00:00 AM
Fortinet Inc (FTNT) · Earnings Release
Fortinet is expected to release its Q1 2026 earnings report on April 30, 2026, with analysts forecasting EPS of $0.62 and revenue of $1.73B, scheduled.
4/30/2026, 12:00:00 AM
Automatic Data Processing Inc (ADP) · Earnings Release
Automatic Data Processing is estimated to report its Q3 2026 earnings on or around April 29, 2026, based on past reporting schedules. As earnings reports typically trigger price movements of 5-10%, importance is estimated as Medium, scheduled.
4/29/2026, 12:00:00 AM